🇺🇸 FDA
Pipeline program

CS1001

CS1001/Regorafenib-101

Phase 2 small_molecule completed

Quick answer

CS1001 for Advanced Refractory Solid Tumors is a Phase 2 program (small_molecule) at Cstone Pharmaceuticals Ireland Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Cstone Pharmaceuticals Ireland Limited
Indication
Advanced Refractory Solid Tumors
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials